Incannex Healthcare Files 2024 Annual Report

TL;DR

Incannex Healthcare filed its 2024 10-K. All systems go for now.

AI Summary

Incannex Healthcare Inc. filed its annual report (10-K) for the fiscal year ended June 30, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector. Its principal executive offices are located in Norwest, NSW, Australia, with a business phone number of +61 409 840 786. The filing covers the period up to June 30, 2024, and was submitted on September 30, 2024.

Why It Matters

This filing provides a comprehensive overview of Incannex Healthcare's financial performance and operational status for the past fiscal year, crucial for investors and stakeholders to assess the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Incannex Healthcare faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

• 2024 — Fiscal Year End (The report covers the fiscal year ending on this date.)
• 20240930 — Filing Date (The date the 10-K was officially submitted to the SEC.)

Key Players & Entities

• Incannex Healthcare Inc. (company) — Registrant
• June 30, 2024 (date) — Fiscal year end
• September 30, 2024 (date) — Filing date
• 001-41106 (dollar_amount) — SEC file number
• Delaware (company) — State of incorporation
• +61 409 840 786 (dollar_amount) — Business phone number

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IXHL The Nasdaq Glo
• $4.64 — ed by reference to the closing price of $4.64 of the common stock on the Nasdaq Globa
• $8.2 b — opportunity for OSA is approximately US$8.2 billion, with an estimated compound annua
• $21 billion — e United States reached approximately US$21 billion in 2023. The rheumatoid arthritis marke
• $25.37 billion — umatoid arthritis treatments reaching US$25.37 billion in 2023. This market is expected to exc
• $31.58 billion — 23. This market is expected to exceed US$31.58 billion by 2033. We believe that our leading dr
• $3.6 billion — nditions in the United States totaled US$3.6 billion in 2022. Clinical Approach In our i
• $8.2 billion — arket for sleep apnea devices is over US$8.2 billion and growing. The estimated compound ann

Filing Documents

• ea0212488-10k_incannex.htm (10-K) — 1598KB
• ea021248801ex4-2_incannex.htm (EX-4.2) — 263KB
• ea021248801ex10-9_incannex.htm (EX-10.9) — 60KB
• ea021248801ex19-1_incannex.htm (EX-19.1) — 42KB
• ea021248801ex21-1_incannex.htm (EX-21.1) — 5KB
• ea021248801ex23-1_incannex.htm (EX-23.1) — 2KB
• ea021248801ex31-1_incannex.htm (EX-31.1) — 10KB
• ea021248801ex31-2_incannex.htm (EX-31.2) — 10KB
• ea021248801ex32-1_incannex.htm (EX-32.1) — 4KB
• ea021248801ex32-2_incannex.htm (EX-32.2) — 4KB
• ea021248801ex97-1_incannex.htm (EX-97.1) — 25KB
• image_001.jpg (GRAPHIC) — 118KB
• image_002.jpg (GRAPHIC) — 51KB
• image_003.jpg (GRAPHIC) — 41KB
• image_004.jpg (GRAPHIC) — 34KB
• ex19-1_001.jpg (GRAPHIC) — 11KB
• ex97-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-082937.txt ( ) — 7239KB
• ixhl-20240630.xsd (EX-101.SCH) — 58KB
• ixhl-20240630_cal.xml (EX-101.CAL) — 33KB
• ixhl-20240630_def.xml (EX-101.DEF) — 217KB
• ixhl-20240630_lab.xml (EX-101.LAB) — 416KB
• ixhl-20240630_pre.xml (EX-101.PRE) — 231KB
• ea0212488-10k_incannex_htm.xml (XML) — 651KB

Risk Factors

Item 1A. Risk Factors 35

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 75

Cybersecurity

Item 1C. Cybersecurity 76

Properties

Item 2. Properties 77

Legal Proceedings

Item 3. Legal Proceedings 77

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 77 PART II 78

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 78

[Reserved]

Item 6. [Reserved] 78

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 79

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 86

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data F-1

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 87

Controls and Procedures

Item 9A. Controls and Procedures 87

Other Information

Item 9B. Other Information 88

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 88 PART III 89

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 89

Executive Compensation

Item 11. Executive Compensation 92

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 97

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 101

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 103 PART IV 104

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 104

Form 10-K Summary

Item 16. Form 10-K Summary 105

Signatures

Signatures 106 i Trademarks We own or have rights to trademarks and trade names that we use in connection with the operation of our business, including our corporate name, logos, product names and website names. Solely for your convenience, some of the trademarks and trade names referred to in this annual report on Form 10-K for the fiscal year ended June 30, 2024 ("Annual Report") are listed without the and TM symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks and trade names. S tatistical and O ther I ndustry and M arket D ata This Annual Report includes statistical and other industry and market data and contains estimates and information concerning our industry and our business, including estimated market size and projected growth rates of the markets for our drug candidates. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other information from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. This information involves a number of assumptions and limitations. Although we are responsible for all of the disclosure contained in this Annual Report and we believe the third-party market position, market opportunity and market size data included in this Annual Report are reliable, we have not independently verified the accuracy or completeness of this third-party data. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in "Risk Factors." These and other factors could cause results to differ materially from those expressed in these publications and reports. Special Note Regarding Forward-Looking Statements This Annual Report contains forward-looking

Business

Item 1. Business Overview We are a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with serious chronic diseases and significant unmet needs. Our lead drug candidates are currently in Phase 2/3 and Phase 2 clinical development. IHL-42X, our drug candidate in a pivotal Phase 2/3 for the treatment of obstructive sleep apnea ("OSA") is an oral fixed dose combination of dronabinol and acetazolamide designed to act synergistically, targeting two different physiological pathways associated with the intermittent hypoxia and hypercapnia that characterize OSA. In a proof-of-concept Australian Phase 2 clinical trial, we observed that IHL-42X reduced apnea hypopnea index ("AHI") and was well tolerated in OSA patients. The ongoing Phase 2/3 clinical trial further investigates the safety and efficacy of IHL-42X for the treatment of OSA. The Phase 2 portion is being conducted in the United States, and the expanded Phase 3 portion will include the United Kingdom and European Union. We expect to report top-line data from the Phase 2 portion this pivotal U.S. Phase 2/3 clinical trial in the first half of 2025 and to release top-line results from our pharmacokinetic and safety study in 2024. PSX-001, our drug candidate in Phase 2b clinical development, is an oral synthetic psilocybin treatment, administered in combination with psychological therapy for patients with moderate-to-severe generalized anxiety disorder ("GAD"). We completed a proof-of-concept clinical trial, known as PsiGAD1, in the top-line results of which we observed that the combination of synthetic psilocybin with psychotherapy significantly reduced anxiety scores and was well tolerated in GAD patients. We have received clearance of an Investigational New Drug ("IND") application from the U.S. Food and Drug Administration ("FDA") to conduct a Phase 2b clinical trial to further investigate the safety and efficacy of PSX-001 for treatment of GAD. We anticip

View Full Filing

View this 10-K filing on SEC EDGAR